Related Experiment Video
Updated: Jul 10, 2026

Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency
Published on: February 2, 2024
Pancreatic Cancer: Genetics, Screening, Prevention, and Treatment.
Sami O Abul-Khoudoud1, Jeffrey M Hardacre2
1Department of Surgery, Division of Surgical Oncology, University Hospitals, Cleveland Medical Center, 11100 Euclid Avenue, Cleveland, OH 44106, USA.
Pancreatic cancer, particularly pancreatic ductal adenocarcinoma (PDAC), is a deadly disease with poor survival rates. Research focuses on understanding its complex genetic and environmental drivers to develop better treatments and improve patient outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genetics
Background:
- Pancreatic cancer has a low 5-year survival rate (13%), with pancreatic ductal adenocarcinoma (PDAC) having a worse prognosis.
- PDAC's aggressiveness stems from intricate genetic, epigenetic, and microenvironmental changes.
- Key mutations (KRAS, CDKN2A, TP53, SMAD4) drive PDAC tumorigenesis, genomic instability, and treatment resistance.
Purpose of the Study:
- To enhance understanding of PDAC biology through molecular profiling.
- To identify actionable mutations and potential therapeutic targets for PDAC.
- To address limitations in current targeted therapies and improve patient outcomes.
Main Methods:
- Molecular profiling of pancreatic tumors.
- Analysis of genetic and epigenetic alterations.
- Review of ongoing research in therapeutic strategies.
Main Results:
- Advances in molecular profiling have improved understanding of PDAC biology.
- Identification of specific driver mutations contributing to PDAC progression.
- Recognition of limited effectiveness of current targeted therapies.
Conclusions:
- Further research is needed to refine patient selection for therapies.
- Optimizing treatment strategies is crucial for improving PDAC outcomes.
- Continued investigation into PDAC's complex biology is essential for therapeutic advancements.
Related Concept Videos
Cancer Prevention
Some...
Cancer Prevention
Some...
Chronic Pancreatitis II: Collaborative Care
Assessment:
Preventive Healthcare Services
Chronic Pancreatitis I: Introduction
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...